Resource Summary

Clinical Question:
In Type 2 Diabetes^ do dipeptidyl peptidase-4 (DPP-4) inhibitors affect outcomes [like cardiovascular disease (CVD)] other than glucose?

Bottom-line:
While DPP-4 inhibitors lower A1c by 0.3-0.8 percent^ they do not modify CVD or mortality. Adverse events were generally uncommon^ but a tiny risk of pancreatitis remains possible^ and saxagliptin increased hypoglycemia (-1 in 50) and heart failure (-1 in 150).


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2015-11-9
Last Updated on PCR: 2017-03-31 14:54:53